Pruritus, or itching, is a bothersome symptom linked to many skin and systemic disorders, significantly impacting patients' lives. Traditional treatments like antihistamines and corticosteroids often fall short, causing systemic side effects and delivering less than optimal results. Nanotechnology, particularly using nanoparticles, provides a highly sophisticated approach to drug delivery. Nanoparticles enable targeted delivery of therapeutic agents by recognizing and binding to cellular receptors or inflammatory pathways associated with pruritus. To enhance drug penetration and retention in the skin, spherical lipid bilayer vesicles, known as liposomes, can encapsulate hydrophilic and lipophilic drugs. This technology maximizes therapeutic benefits while minimizing systemic absorption and toxicity. Microneedle systems, another advanced technology, use arrays of tiny needles to painlessly penetrate the skin and deliver drugs directly to the dermal layer. This method enhances drug bioavailability and allows for localized pruritus treatment with minimal discomfort and side effects. New therapies are investigating novel drug formulations and molecular targets, with clinical trials evaluating the effectiveness of these advanced delivery systems in the management of pruritus. Pharmacogenomics and precision medicine further customize treatment protocols by tailoring therapies to individual genetic profiles and specific pruritus causes. These approaches promise more effective, patient-centric care, ultimately improving therapeutic outcomes and the quality of life for those suffering from pruritus. Overall, targeted drug delivery systems are transforming pruritus treatment, providing a more refined and effective way to manage this challenging symptom.
Firdous et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: